Search Result

Pathways Recommended:	Stem Cell/Wnt Cell Cycle/DNA Damage

Results for "

PBMC cell

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Itk (1) 11β-HSD (1) Apoptosis (6) Biochemical Assay Reagents (1) Caspase (1) CCR (1) CD20 (1) CD3 (2) CD6 (1) CRAC Channel (1) CXCR (3) Dipeptidyl Peptidase (1) Endogenous Metabolite (3) Eukaryotic Initiation Factor (eIF) (2) Glucocorticoid Receptor (1) HIV (18) HIV Protease (3) IFNAR (4) IKK (2) Interleukin Related (3) IRAK (2) Isotope-Labeled Compounds (1) JAK (1) Kinesin (1) Ligands for E3 Ligase (1) MAP4K (2) Mineralocorticoid Receptor (1) MMP (3) NF-κB (1) NOD-like Receptor (NLR) (2) Nucleoside Antimetabolite/Analog (1) PD-1/PD-L1 (5) PROTACs (1) Proteasome (1) Reverse Transcriptase (3) ROR (3) SARS-CoV (3) STING (1) TGF-beta/Smad (1) TNF Receptor (2) Toll-like Receptor (TLR) (7)
By Research Areas:	Cancer (26) Endocrinology (3) Infection (20) Inflammation/Immunology (30) Metabolic Disease (3) Neurological Disease (1)
Click Chemistry:	Azide (1)

Inhibitors & Agonists

Peptides

MCE Kits

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Targets Recommended: Itk TOPK NAMPT ALCAM/CD166 GDNF Receptor BCL6 Tim3

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-150749A

ODN D-SL03 sodium	IFNAR	Cancer
ODN D-SL03 sodium is a C class CpG oligonucleotides, and can induce stimulate PBMCs to produce high level of IFN-α. ODN D-SL03 sodium can activate human B cells, NK cells and mononuclear cells and up-regulate expression of CD80, CD86 and HLA-DR on the surface of subsets in human PBMCs. ODN D-SL03 sodium also can inhibit the growth of the tumor. ODN D-SL03 sequence: 5'-tcgcgaacgttcgccgcgttcgaacgcgg-3' .

HY-150749

ODN D-SL03	IFNAR	Inflammation/Immunology Cancer
ODN D-SL03 is a C class CpG oligonucleotides, can induce stimulate PBMCs to produce high level of IFN-α. ODN D-SL03 can activate human B cells, NK cells and mononuclear cells and up-regulate expression of CD80, CD86 and HLA-DR on the surface of subsets in human PBMCs. ODN D-SL03 also can inhibit the growth of the tumor. ODN D-SL03 sequence: 5'-tcgcgaacgttcgccgcgttcgaacgcgg-3' .

HY-P4984

Toxic Shock Syndrome Toxin-1 (TSST-1) (58-78)	Biochemical Assay Reagents	Inflammation/Immunology Cancer
Toxic Shock Syndrome Toxin-1 (TSST-1) (58-78) is a T cell proliferation activator. Toxic Shock Syndrome Toxin-1 (TSST-1) (58-78) promotes the in vitro proliferation of human peripheral blood mononuclear cells (PBMC) in a dose-dependent manner. Toxic Shock Syndrome Toxin-1 (TSST-1) (58-78) can be used in research on inflammatory and immunity, as well as cancer .

HY-149356

PD-1/PD-L1-IN-31	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-31 is a PD-1/PD-L1 inhibitor (IC₅₀=2.2 nM). PD-1/PD-L1-IN-31 promotes secretion of the IFN-γ, and induces immune activity of peripheral blood mononuclear cells (PBMCs) to inhibits tumor cells .

HY-147506

NOD2 antagonist 1	NOD-like Receptor (NLR)	Inflammation/Immunology
NOD2 antagonist 1 (compound 32) is a potent and selective NOD2 antagonist with an IC₅₀ of 5.23 μM. NOD2 antagonist 1 inhibits Muramyl dipeptide (MDP)-induced IL-8 secretion in THP-1 cells and inhibits MDP-induced IL-6, IL-10, TNF-α release in PBMCs .

HY-103697

Gardiquimod	Toll-like Receptor (TLR) HIV	Infection Cancer
Gardiquimod, an imidazoquinoline analog, is a TLR7/8 agonist. Gardiquimod could inhibit HIV-1 infection of macrophages and activated peripheral blood mononuclear cells (PBMCs). Gardiquimod specifically activates TLR7 when used at concentrations below 10 μM .

HY-103697A

Gardiquimod diTFA	Toll-like Receptor (TLR) HIV	Infection Cancer
Gardiquimod diTFA, an imidazoquinoline analog, is a TLR7/8 agonist. Gardiquimod diTFA could inhibit HIV-1 infection of macrophages and activated peripheral blood mononuclear cells (PBMCs). Gardiquimod diTFA specifically activates TLR7 when used at concentrations below 10 μM .

HY-151871

ICeD-2	Dipeptidyl Peptidase HIV	Infection
ICeD-2 is a inducer of cell death, can induce HIV-1 infected cell kill. ICeD-2-mediated HIV-1 infected cell kill is dependent on HIV-1 protease activity. ICeD-2 potently blocks hydrolysis of Gly-Pro-AMC by dipeptidyl peptidase DPP8 and DPP9. ICeD-2 shows strong stabilization of DPP9 in PBMCs .

HY-143305

PD-1/PD-L1-IN-25	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-25 (compound D2) is an inhibitor of PD-1/PD-L1 interaction with an IC₅₀ value of 16.17 nM. PD-1/PD-L1-IN-25 activates the antitumor immunity of T cells efficiently in PBMCs. PD-1/PD-L1-IN-25 can be used for the research of cancer .

HY-144649

PD-1/PD-L1-IN-24	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-24 is a highly potent PD-1/PD-L1 inhibitor with IC₅₀ value of 1.57 nM. PD-1/PD-L1-IN-24 can restore T-cell function at the cellular level by significantly elevating the IFN-γ level. PD-1/PD-L1-IN-24 has low toxicity on the PBMCs .

HY-135382

PROTAC IRAK4 degrader-2	PROTACs IRAK	Inflammation/Immunology Cancer
PROTAC IRAK4 degrader-2 (Compound 9) is a PROTAC-based IRAK4 degrader that affords potent IRAK4 degradation with a DC₅₀ in peripheral blood mononuclear cells (PBMCs) cells of 151 nM. PROTAC IRAK4 degrader-2 induce a reduction of IRAK4 protein levels with a DC₅₀ of 36 nM in PBMC cells. PROTAC IRAK4 degrader-2 also leads to the inhibition of multiple cytokines in PBMCs .

HY-17427

Emtricitabine 4 Publications Verification BW1592	HIV Reverse Transcriptase Endogenous Metabolite	Infection
Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) with an EC₅₀ of 0.01 μM in PBMC cell. It is an antiviral agent for the treatment of HIV infection.

HY-17427R

Emtricitabine (Standard) BW1592 (Standard)	HIV Reverse Transcriptase Endogenous Metabolite	Infection
Emtricitabine (Standard) is the analytical standard of Emtricitabine. This product is intended for research and analytical applications. Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) with an EC₅₀ of 0.01 μM in PBMC cell. It is an antiviral agent for the treatment of HIV infection.

HY-100870

Obefazimod ABX464	HIV	Infection
Obefazimod (ABX464) is a potent anti-HIV agent. Obefazimod inhibits HIV-1 replication in stimulated peripheral blood mononuclear cells (PBMCs) with an IC₅₀ ranging between 0.1 μM and 0.5 μM.

HY-19775

GNE-6468	ROR	Inflammation/Immunology
GNE-6468 is a highly potent and selective RORγ (RORc) inverse agonist with an EC₅₀ value of 13 nM for HEK-293 cell. GNE-6468 exhibits an EC₅₀ of 30 nM for IL-17 PBMC .

HY-17427S

Emtricitabine-15N,d2 BW1592-¹⁵N,d₂	HIV Reverse Transcriptase Endogenous Metabolite	Infection
Emtricitabine- ¹⁵N,d₂ is a ¹⁵N-labeled and deuterium labeled Emtricitabine. Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) with an EC50 of 0.01 μM in PBMC cell. It is an antiviral agent for the treatment of HIV infection.

HY-148643

STING modulator-5	STING	Inflammation/Immunology
STING modulator-5 (compound 38) is a STING modulator with a pIC₅₀ value of 9.5. STING modulator-5 antagonizes peripheral blood mononuclear cells (PBMC) with a pIC₅₀ value of 8.1. STING modulator-5 is a antagonist of THP-1 cells, it can be used for immunological disease research .

HY-N1196

Suberosin	NF-κB	Inflammation/Immunology
Suberosin, isolated from Plumbago zeylanica, exhibits anti-inflammatory and anticoagulant activity. Suberosin suppresses PHA-induced PBMC proliferation and arrested cell cycle progression from the G1 transition to the S phase through the modulation of the transcription factors NF-AT and NF-κB .

HY-13224

AZD4877	Kinesin Apoptosis	Cancer
AZD4877 is another isostere to Ispinesib (HY-50759)and also a kinesin spindle protein (Eg5) inhibitor with IC₅₀ of 2 nM.AZD4877 arrests cell mitosis, leads to the formation of the monopolar spindle phenotype and induces apoptosis. AZD4877 inhibits circulating peripheral blood mononuclear cells (PBMCs) and has anti-cancer activity .

HY-19836

Zimlovisertib 3 Publications Verification PF-06650833	IRAK	Inflammation/Immunology
Zimlovisertib (PF-06650833) is a potent, selective and orally active inhibitor of interleukin-1 receptor associated kinase 4 (IRAK4) with IC₅₀s of 0.2 and 2.4 nM in the cell and PBMC assay, respectively. Zimlovisertib is used to treat diseases such as rheumatoid arthritis, lupus, and lymphomas .

HY-17427S2

Emtricitabine-13C,15N2 BW1592-¹³C,15N₂	Isotope-Labeled Compounds	Infection
Emtricitabine- ¹³C, ¹⁵N₂ (BW1592- ¹³C, ¹⁵N₂) is a ¹³C- and ¹⁵N-labeled Emtricitabine (HY-17427). Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) with an EC₅₀ of 0.01 μM in PBMC cell. It is an antiviral agent for the treatment of HIV infection.

HY-138568

HPK1-IN-3	MAP4K	Inflammation/Immunology
HPK1-IN-3 is a potent and selective ATP-competitive hematopoietic progenitor kinase 1 (HPK1; MAP4K1) inhibitor with an IC₅₀ of 0.25 nM. HPK1-IN-3 has IL-2 cellular potency with an EC₅₀ of 108 nM in human peripheral blood mononuclear cells (PBMCs) .

HY-17377

Vicriviroc maleate SCH-417690 maleate; SCH-D maleate	CCR HIV	Infection Endocrinology
Vicriviroc maleate (SCH-417690 maleate; SCH-D maleate) is a potent, selective, oral bioavailable and CNS penetrated antagonist of CCR5, with a K_i of 2.5 nM, and also inhibits HIV-1 in PBMC cells, with IC₉₀s of 3.3 nM (JrFL), 2.8 nM (ADA-M), 1.8 nM (301657), 4.9 nM (JV1083) and 10 nM (RU 570).

HY-50101A

Mavorixafor trihydrochloride 5+ Cited Publications AMD-070 trihydrochloride	CXCR HIV	Infection Endocrinology Cancer
Mavorixafor trihydrochloride (AMD-070 trihydrochloride) is a potent, selective and orally available CXCR4 antagonist, with an IC₅₀ value of 13 nM against CXCR4 ¹²⁵I-SDF binding, and also inhibits the replication of T-tropic HIV-1 (NL4.3 strain) in MT-4 cells and PBMCs with an IC₅₀ of 1 and 9 nM, respectively.

HY-50101

Mavorixafor AMD-070	CXCR HIV	Infection Endocrinology Cancer
Mavorixafor (AMD-070) is a potent, selective and orally available CXCR4 antagonist, with an IC₅₀ value of 13 nM against CXCR4 ¹²⁵I-SDF binding, and also inhibits the replication of T-tropic HIV-1 (NL4.3 strain) in MT-4 cells and PBMCs with an IC₅₀ of 1 and 9 nM, respectively.

HY-158024

NDT-19795	NOD-like Receptor (NLR)	Neurological Disease
NDT-19795 is an effective inhibitor of the NLRP3 inflammasome with an IC₅₀ value of 66 nM in the PBMC method and 4.7 μM in the WB method. NDT-19795 is a carboxylic acid-active substance that can be converted from NT-0796 (HY-156438) within cells. NDT-19795 can be used for the study of neurological diseases .

HY-147832

EIF2α activator 2	Eukaryotic Initiation Factor (eIF)	Cancer
EIF2α activator 2 (Compound 1) is an activator of eukaryotic initiation factor 2 alpha (eIF2α) phosphorylation. EIF2α activator 2 exhibits high potency in SRB cell proliferation assays (IC₅₀=0.46 μM). EIF2α activator 2 exhibits antiproliferative activity againist K562 and PBMC cells with IC₅₀s of 4.79 and 10.52 μM, respectively .

HY-50101C

Mavorixafor hydrochloride AMD-070 hydrochloride	CXCR HIV	Infection Cancer
Mavorixafor (AMD-070) hydrochloride is a potent, selective and orally available CXCR4 antagonist, with an IC₅₀ value of 13 nM against CXCR4 ¹²⁵I-SDF binding. Mavorixafor hydrochloride also inhibits the replication of T-tropic HIV-1 (NL4.3 strain) in MT-4 cells and PBMCs with an IC₅₀ of 1 nM and 9 nM, respectively .

HY-P99931

Epcoritamab GEN3013	CD3 CD20	Cancer
Epcoritamab (GEN3013) is an bispecific IgG1 antibody redirecting T-cells toward CD3×CD20 ⁺ tumor cells. Epcoritamab induces potent T-cell-mediated cytotoxicity towards B-cell NHL cell lines .

HY-P3143A

BMSpep-57 hydrochloride	PD-1/PD-L1	Cancer
BMSpep-57 hydrochloride is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction with an IC₅₀ of 7.68 nM. BMSpep-57 hydrochloride binds to PD-L1 with K_ds of 19 nM and 19.88 nM in MST and SPR assays, respectively. BMSpep-57 hydrochloride facilitates T cell function by in creasing IL-2 production in PBMCs .

HY-150741

ODN 2216	Toll-like Receptor (TLR) IFNAR Interleukin Related	Infection Inflammation/Immunology Cancer
ODN 2216 is a human-specific TLR9 (toll-like receptor 9) ligand or agonist. ODN 2216 induces high amounts of IFN-α and IFN-β. ODN 2216 induces IFN-α by pDC (plasmacytoid DC) and IL-12 (p40) production by DC (dendritic cells). ODN 2216 stimulates IFN-γ production in peripheral blood mononuclear cells (PBMC), which is indirect and mediated by IFN-α/β. ODN 2216 can activate NK cells and promote IFN-γ production of TCR-triggered CD4 ⁺ T cells .

HY-150741C

ODN 2216 sodium	Toll-like Receptor (TLR)	Cancer
ODN?2216 sodium is a human-specific TLR9 (toll-like receptor 9) ligand or agonist. ODN?2216 sodium induces high amounts of IFN-α and IFN-β. ODN 2216 sodium induces IFN-α by pDC (plasmacytoid DC) and IL-12 (p40) production by DC (dendritic cells). ODN 2216 sodium stimulates IFN-γ production in peripheral blood mononuclear cells (PBMC), which is indirect and mediated by IFN-α/β. ODN 2216 sodium can activate NK cells and promote IFN-γ production of TCR-triggered CD4 ⁺ T cells .

HY-111964

Lenacapavir 5+ Cited Publications GS-6207	HIV	Infection
Lenacapavir (GS-6207) is a HIV-1 capsid inhibitor. Lenacapavir shows anti-HIV activity with an EC₅₀ of 100 pM in MT-4 cells. Lenacapavir displays a mean EC₅₀ of 50 pM (20-160 pM) against 23 HIV-1 clinical isolates from different subtypes in peripheral blood mononuclear cells (PBMCs) . Lenacapavir is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-P3143

BMSpep-57	PD-1/PD-L1	Cancer
BMSpep-57 is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction with an IC₅₀ of 7.68 nM. BMSpep-57 binds to PD-L1 with K_ds of 19 nM and 19.88 nM in MST and SPR assays, respectively. BMSpep-57 facilitates T cell function by in creasing IL-2 production in PBMCs .

HY-W105318

Pentabromophenol PBP	TGF-beta/Smad Apoptosis	Cancer
Pentabromophenol (PBP) is a brominated flame retardant (BFR) widely used in various consumer products to reduce the flammability of materials used in different utility items. Pentabromophenol can accelerate the degradation of transforming growth factor-β (TGF-β) receptors by promoting clathrin-mediated endocytosis, thereby inhibiting the TGF-β signaling pathway. Additionally, Pentabromophenol can also induce apoptosis in peripheral blood mononuclear cells (PBMCs) .

HY-147831

EIF2α activator 1	Eukaryotic Initiation Factor (eIF)	Cancer
EIF2α activator 1 (Compound 40) is an activator of eukaryotic initiation factor 2 alpha (eIF2α) phosphorylation. EIF2α activator 1 increases the expression level of eIF2α downstream proteins, ATF and CHOP. EIF2α activator 1 exhibits antiproliferative activity againist K562 and PBMC cells with IC₅₀s of 4.00 and 19.3 μM, respectively .

HY-120559

GSK-2250665A

Itk Inflammation/Immunology

GSK-2250665A (Compound 13) is a selective Itk inhibitor with a pK_i of 9.2.

GSK-2250665A	Itk	Inflammation/Immunology
GSK-2250665A (Compound 13) is a selective Itk inhibitor with a pK_i of 9.2.

HY-113953

Z-Asp-CH2-DCB	Caspase Apoptosis	Inflammation/Immunology
Z-Asp-CH2-DCB is an irreversible broad spectrum caspase inhibitor. Z-Asp-CH2-DCB also inhibits proteases with caspase-like activity. Z-D-CH2-DCB blocks the production of IL-1β, TNF-α, IL-6, and IFN-γ in staphylococcal enterotoxin B (SEB)-stimulated peripheral blood mononuclear cells (PBMC), and reduces SEB-1-stimulated T-cell proliferation in a dose-dependent manner. Z-Asp-CH2-DCB prevents SU5416-induced septal cell apoptosis and emphysema development .

HY-150738

ODN 2088	Toll-like Receptor (TLR)	Inflammation/Immunology
ODN 2088 is a potent TLR3, TLR7 and TLR9 inhibitor. ODN 2088 shows no cytotoxic. ODN 2088 inhibits the release of IFN-α and IL-6 .

HY-150738C

ODN 2088 sodium	Nucleoside Antimetabolite/Analog	Inflammation/Immunology
ODN 2088 sodium is a potent TLR3, TLR7 and TLR9 inhibitor. ODN 2088 sodium shows no cytotoxic. ODN 2088 inhibits the release of IFN-α and IL-6 .

HY-150745

ODN 24987	Toll-like Receptor (TLR)	Inflammation/Immunology
ODN 24987 is a Guanine-modified inhibitory oligonucleotides (ODN), targeting TLR9. ODN 24987 can inhibit IL-6 and IFN-α release. ODN 24987 can be used for research immune disorders. ODN 24987 sequence: 5’-C-C-T-G-G-C-c7G-G-G-G-3’ .

HY-P99222

Teplizumab MGA-031; PRV-031	CD3	Metabolic Disease
Teplizumab (MGA-031) is a Fc receptor non-binding anti-human CD3 monoclonal antibody. Teplizumab reduces the loss of beta-cell function. Teplizumab can be used in the research of type 1 diabetes .

HY-161335

HPK1-IN-43	MAP4K Interleukin Related IFNAR	Cancer
HPK1-IN-43 (compound 9f) is a HPK1 kinase inhibitor with the IC₅₀ value of 0.32 nM. HPK1-IN-43 inhibits the phosphorylation of the downstream protein SLP-76 and enhances the secretion of interleukin-2 (IL-2) and interferon-γ (IFN-γ). HPK1-IN-43 can be used in cancer research .

HY-12521

GSK-5498A 3 Publications Verification	CRAC Channel	Inflammation/Immunology
GSK-5498A is a selective CARC channel inhibitor (IC₅₀: 1 μM). GSK-5498A inhibits mediators release from mast cells and pro-inflammatory cytokines release from T cells. GSK-5498A can be used in the research of inflammatory disorders .

HY-P990090

Rademikibart CBP-201	Interleukin Related	Inflammation/Immunology
Rademikibart (CBP-201) is a human monoclonal antibody targeting IL-4Rα with a KD of 20.7 pM when binding to human IL-4Rα epitopes. Rademikibart does not bind to IL-4Rα from other species. Rademikibart inhibits IL-4 and IL-13-mediated STAT6 signaling, TF-1 cell proliferation and TARC production in PBMCs. Rademikibart has the potential for moderate-to-severe Th2 inflammatory diseases research .

HY-106850

3′-Azido-2′,3′-dideoxyuridine AzdU; AzddU; CS-87	HIV	Infection
3′-Azido-2′,3′-dideoxyuridine (AzdU) is a nucleoside analog of Zidovudine (HY-17413). 3′-Azido-2′,3′-dideoxyuridine is a potent inhibitor of human immunodeficiency virus (HIV) replication in human peripheral blood mononuclear cells (PBMC) with limited toxicity for human bone marrow cells (BMC) . 3′-Azido-2′,3′-dideoxyuridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. Strain-promoted alkyne-azide cycloaddition (SPAAC) can also occur with molecules containing DBCO or BCN groups.

HY-117937

BC-1215 1 Publications Verification	Ligands for E3 Ligase	Inflammation/Immunology
BC-1215 is a F-box protein 3 (Fbxo3) inhibitor. BC-1215 works by antagonizing of Fbxo3 on TRAF cytokine signaling and exhibits a low IC₅₀ in vitro. BC-1215 can be used for the research of inflammation .

HY-B0689

Indinavir MK-639 free base; L-735524 free base	HIV HIV Protease Apoptosis MMP SARS-CoV	Inflammation/Immunology Cancer
Indinavir (MK-639 free base) is an orally active and selective HIV-1 protease inhibitor with a K_i of 0.54 nM for PR. Indinavir exhibits anticancer activity by inhibiting the activation of MMPs-2 hydrolysis, anti-angiogenesis and inducing apoptosis. Indinavir is also a SARS-CoV 3CL ^pro inhibitor .

HY-B0689A

Indinavir sulfate Maximum Cited Publications 8 Publications Verification MK-639; L735524	HIV HIV Protease SARS-CoV Apoptosis MMP	Infection Cancer
Indinavir sulfate (MK-639) is an orally active and selective HIV-1 protease inhibitor with a K_i of 0.54 nM for PR. Indinavir sulfate exhibits anticancer activity by inhibiting the activation of MMPs-2 hydrolysis, anti-angiogenesis and inducing apoptosis. Indinavir sulfate is also a SARS-CoV 3CL ^pro inhibitor .

HY-B0689B

Indinavir sulfate ethanolate MK-639 ethanolate; L735524 ethanolate	Apoptosis MMP HIV HIV Protease SARS-CoV	Infection Cancer
Indinavir sulfate ethanolate (MK-639 ethanolate) is an orally active and selective HIV-1 protease inhibitor with a K_i of 0.54 nM for PR. Indinavir sulfate ethanolate exhibits anticancer activity by inhibiting the activation of MMPs-2 hydrolysis, anti-angiogenesis and inducing apoptosis. Indinavir sulfate ethanolate is also a SARS-CoV 3CL ^pro inhibitor .

Cat. No.	Product Name	Target	Research Area

HY-P99931

Epcoritamab GEN3013	CD3 CD20	Cancer
Epcoritamab (GEN3013) is an bispecific IgG1 antibody redirecting T-cells toward CD3×CD20 ⁺ tumor cells. Epcoritamab induces potent T-cell-mediated cytotoxicity towards B-cell NHL cell lines .

HY-P99222

Teplizumab MGA-031; PRV-031	CD3	Metabolic Disease
Teplizumab (MGA-031) is a Fc receptor non-binding anti-human CD3 monoclonal antibody. Teplizumab reduces the loss of beta-cell function. Teplizumab can be used in the research of type 1 diabetes .

HY-P99670

Iscalimab CFZ-533; OM11-62MF	TNF Receptor	Metabolic Disease Inflammation/Immunology
Iscalimab (CFZ-533) is a non-depleting IGg1 monoclonal antibody targeting CD40 (K_D: 0.3 nM). Iscalimab can be used for research of Graves' hyperthyroidism and autoimmune diseases .

HY-P99167

Lucatumumab HCD122	TNF Receptor	Cancer
Lucatumumab (HCD122) is a fully human anti-CD40 antagonist monoclonal antibody, which blocks CD40/CD40L-mediated signaling. Lucatumumab efficiently mediates antibody-dependent cell-mediated cytotoxicity (ADCC) and clearance of tumor cells, can be used for refractory lymphomas, CLL and multiple myeloma research .

HY-P990090

Rademikibart CBP-201	Interleukin Related	Inflammation/Immunology
Rademikibart (CBP-201) is a human monoclonal antibody targeting IL-4Rα with a KD of 20.7 pM when binding to human IL-4Rα epitopes. Rademikibart does not bind to IL-4Rα from other species. Rademikibart inhibits IL-4 and IL-13-mediated STAT6 signaling, TF-1 cell proliferation and TARC production in PBMCs. Rademikibart has the potential for moderate-to-severe Th2 inflammatory diseases research .

HY-P99168

Anifrolumab	Inhibitory Antibodies	Inflammation/Immunology
Anifrolumab is a type I interferon (IFN) receptor antagonist, a human monoclonal antibody. Anifrolumab blocks the activity of type I interferon. Anifrolumab can be used in systemic lupus erythematosus (SLE) research .

HY-P99252

Itolizumab Anti-Human CD6 Recombinant Antibody	CD6	Infection Inflammation/Immunology
Itolizumab (Anti-Human CD6 Recombinant Antibody) is a humanized recombinant anti-CD6 monoclonal antibody (MAb) targeting the extracellular SRCR distal domain 1 of CD6. Itolizumab reduces T-cell proliferation and inhibits the production of pro-inflammatory cytokines, such as INF-γ, TNFα and IL-6. Itolizumab can be used in the research of psoriasis, rheumatoid arthritis (RA), COVID-19 .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-17427

Emtricitabine 4 Publications Verification BW1592	Infection Structural Classification Natural Products Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields	HIV Reverse Transcriptase Endogenous Metabolite
Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) with an EC₅₀ of 0.01 μM in PBMC cell. It is an antiviral agent for the treatment of HIV infection.

HY-N1196

Suberosin	Structural Classification Classification of Application Fields Source classification Coumarins Phenylpropanoids Umbelliferae Plants Pluchea indica (L.) Less. Inflammation/Immunology Disease Research Fields	NF-κB
Suberosin, isolated from Plumbago zeylanica, exhibits anti-inflammatory and anticoagulant activity. Suberosin suppresses PHA-induced PBMC proliferation and arrested cell cycle progression from the G1 transition to the S phase through the modulation of the transcription factors NF-AT and NF-κB .

HY-17427R

Emtricitabine (Standard) BW1592 (Standard)	Structural Classification Natural Products Source classification Endogenous metabolite	HIV Reverse Transcriptase Endogenous Metabolite
Emtricitabine (Standard) is the analytical standard of Emtricitabine. This product is intended for research and analytical applications. Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) with an EC₅₀ of 0.01 μM in PBMC cell. It is an antiviral agent for the treatment of HIV infection.

Cat. No.	Product Name	Chemical Structure

HY-17427S2

Emtricitabine-13C,15N2
Emtricitabine- ¹³C, ¹⁵N₂ (BW1592- ¹³C, ¹⁵N₂) is a ¹³C- and ¹⁵N-labeled Emtricitabine (HY-17427). Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) with an EC₅₀ of 0.01 μM in PBMC cell. It is an antiviral agent for the treatment of HIV infection.

HY-17427S

Emtricitabine-15N,d2
Emtricitabine- ¹⁵N,d₂ is a ¹⁵N-labeled and deuterium labeled Emtricitabine. Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) with an EC50 of 0.01 μM in PBMC cell. It is an antiviral agent for the treatment of HIV infection.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

PBMC cell

Inhibitors & Agonists

Peptides

MCE Kits

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

Click Chemistry

Natural
Products